An androgen receptor N-terminal domain antagonist for treating prostate cancer

Hormone therapies for advanced prostate cancer target the androgen receptor (AR) ligand-binding domain (LBD), but these ultimately fail and the disease progresses to lethal castration-resistant prostate cancer (CRPC). The mechanisms that drive CRPC are incompletely understood, but may involve consti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Myung, Jae-Kyung, Banuelos, Carmen A., Fernandez, Javier Garcia, Mawji, Nasrin R., Wang, Jun, Tien, Amy H., Yang, Yu Chi, Tavakoli, Iran, Haile, Simon, Watt, Kate, McEwan, Iain J., Plymate, Stephen, Andersen, Raymond J., Sadar, Marianne D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Clinical Investigation 2013
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3696543/
https://ncbi.nlm.nih.gov/pubmed/23722902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI66398
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak